{"protocolSection": {"identificationModule": {"nctId": "NCT01525225", "orgStudyIdInfo": {"id": "CV181-153"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM", "officialTitle": "Evaluation of the Pharmacokinetics of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin in Children and Adolescents Aged 10 to 17 Years With Type 2 Diabetes Mellitus Following Oral Administration of Saxagliptin and Metformin XR Fixed Dose Combination Tablet and Co-Administration of Saxagliptin and Glucophage\u00ae (Metformin) IR Tablets"}, "statusModule": {"statusVerifiedDate": "2015-05", "overallStatus": "TERMINATED", "whyStopped": "Release of Post Marketing Requirement for this study. Terminated November 2013.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-09"}, "primaryCompletionDateStruct": {"date": "2013-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-01-31", "studyFirstSubmitQcDate": "2012-01-31", "studyFirstPostDateStruct": {"date": "2012-02-02", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-08-11", "resultsFirstSubmitQcDate": "2014-08-11", "resultsFirstPostDateStruct": {"date": "2014-08-26", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-05-27", "lastUpdatePostDateStruct": {"date": "2015-06-22", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the pharmacokinetics of Saxagliptin, 5-hydroxy Saxagliptin, and Metformin in pediatric subjects with Type 2 diabetes mellitus (T2DM) following oral administration of Saxagliptin and Metformin XR fixed dose combination tablet and co-administration of Saxagliptin and Glucophage\u00ae (Metformin) IR tablets", "detailedDescription": "The primary purpose is to assess the pharmacokinetics of Saxagliptin, 5-hydroxy Saxagliptin, and Metformin in pediatric subjects aged 10 to 17 years with T2DM following oral administration of Saxagliptin and Metformin XR fixed dose combination tablet and co-administration of Saxagliptin and Glucophage\u00ae (Metformin) IR tablets"}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 4, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Metformin immediate release (IR)", "Drug: Saxagliptin", "Drug: Metformin IR", "Drug: Saxagliptin/Metformin XR FDC", "Drug: Metformin XR"]}], "interventions": [{"type": "DRUG", "name": "Metformin immediate release (IR)", "description": "Tablet, Oral, 1000 mg, twice daily, 1 day", "armGroupLabels": ["Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC"], "otherNames": ["Glucophage\u00ae IR"]}, {"type": "DRUG", "name": "Saxagliptin", "description": "Tablet, Oral, 5 mg, single-dose, 1 day", "armGroupLabels": ["Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC"]}, {"type": "DRUG", "name": "Metformin IR", "description": "Tablet, Oral, 1000 mg, twice daily, 5 days", "armGroupLabels": ["Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC"], "otherNames": ["Glucophage\u00ae IR"]}, {"type": "DRUG", "name": "Saxagliptin/Metformin XR FDC", "description": "Tablet, Oral, 2.5 mg Saxagliptin/1000 mg Metformin extended release (XR), Single-dose of 2 tablets. Fixed dose combination (FDC).", "armGroupLabels": ["Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC"]}, {"type": "DRUG", "name": "Metformin XR", "description": "Tablet, Oral, 500 mg, Single-dose of 4 tablets", "armGroupLabels": ["Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC"], "otherNames": ["Glucophage\u00ae XR"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Adverse Events (AEs) , Serious Adverse Events (SAEs), AEs Leading to Discontinuation, Death", "description": "AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.", "timeFrame": "Day 1 up to Day 8, plus 30 days"}], "secondaryOutcomes": [{"measure": "Number of Participants With Marked Chemistry or Hematology Laboratory Abnormalities", "description": "Lower limit of normal (LLN); upper limit of normal (ULN); treatment (RX); pre-treatment (Pre-Rx); units per liter (U/L); millimoles per liter (mmol/L). Alkaline phosphatase U/L:\\>1.25\\*Pre-RX if Pre-RX \\>ULN or \\>1.25\\*ULN if Pre-RX \\<=ULN; aspartate aminotransferase U/L: \\>1.25\\*Pre-RX if Pre-RX\\>ULN or 1.25\\*ULN if Pre-RX\\<=ULN;alanine aminotransferase U/L: \\>1.25\\*Pre-RX if Pre-RX\\>ULN or 1.25\\*ULN if Pre-RX\\<=ULN;blood urea nitrogen mmol/L: \\>1.1\\*ULN if Pre-RX \\<=ULN or \\>1.2\\*Pre-RX if Pre-RX \\>ULN; total bilirubin \u00b5mol/L: \\>1.1\\*ULN if Pre-RX \\<=ULN or \\>1.25\\*Pre-RX if Pre-RX \\>ULN; creatine phosphokinase U/L: \\>1.5\\*Pre-RX if Pre-RX\\>ULN or \\>1.5\\*ULN if Pre-RX \\<= ULN. Grams per liter (g/L); cells per liter (c/L). Hemoglobin (g/L): \\<0.85\\* pre-RX; hematocrit (%): \\<0.85\\*pre-RX;erythrocytes (\\*10\\^12 c/L): \\<0.85\\*pre-RX; platelet count (\\*10\\^9 c/L): \\<0.85\\*LLN if pre-RX\\>=LLN, or if Pre-Tx \\<LLN; leukocytes (\\*10\\^9 c/L): \\<0.85\\*LLN if pre-RX \\<LLN,or \\<0.9\\*LLN if LLN\\<=Pre-RX\\<=ULN.", "timeFrame": "Day 1 to Day 8"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Clinical diagnosis of T2DM\n* Male and female subjects ages 10-17\n* Body weight \u226550 kg\n* Glycosylated hemoglobin (HbA1c) 6.5 to 10%\n\nExclusion Criteria:\n\n* Fasting plasma glucose (FPG) \\> 240 mg/dL at screening\n* Abnormal renal function\n* Active liver disease and/or significant abnormal liver function", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "10 Years", "maximumAge": "17 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Osborne Research Center", "city": "Little Rock", "state": "Arkansas", "zip": "72201", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Axis Clinical Trials", "city": "Los Angeles", "state": "California", "zip": "90036", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Kosair Charities Pediatric Clinical Research Unit", "city": "Louisville", "state": "Kentucky", "zip": "40202", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"facility": "The Children'S Mercy Hospital And Clinics", "city": "Kansas City", "state": "Missouri", "zip": "64108", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"facility": "Promedica Toledo Children'S Hospital", "city": "Toledo", "state": "Ohio", "zip": "43606", "country": "United States", "geoPoint": {"lat": 41.66394, "lon": -83.55521}}, {"facility": "Promedica Toledo Childrens Hospital", "city": "Toledo", "state": "Ohio", "zip": "43606", "country": "United States", "geoPoint": {"lat": 41.66394, "lon": -83.55521}}, {"facility": "Childrens Hospital Of Pittsburgh Of Upmc", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15224", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "BMS clinical trial educational resource", "url": "http://www.bms.com/studyconnect/Pages/home.aspx"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 4 participants were enrolled. Two participants were treated and completed the study prior to the termination of the study.", "recruitmentDetails": "Upon approval of Kombiglyze\u2122 XR, the Food and Drug Administration (FDA) required the conduct of this clinical pharmacology study in pediatric patients as a post-marketing requirement (PMR). Study was initiated February 2013. On 14-Nov-13, the FDA issued a letter stating release from this PMR, thus the study was terminated prior to completion.", "groups": [{"id": "FG000", "title": "Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC", "description": "Each participant received one dose of a 5 mg saxagliptin tablet once a day (QD) and a 1000 mg Glucophage\u00ae immediate release (IR) tablet twice a day (BID) on Day 1. On Days 2 through 6, participants received a 1000 mg tablet of Glucophage\u00ae IR BID, and on Day 7, participants received one dose of two 2.5 mg saxagliptin/1000 mg metformin extended release (XR) fixed dose combination (FDC) tablets. Finally, on Day 8 participants received four 500 mg Glucophage\u00ae IR tablets QD. All study drugs were administered with food."}], "periods": [{"title": "Enrollment", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "No longer met study criteria", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}, {"title": "Treated", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All participants who received at least one dose of study drug.", "groups": [{"id": "BG000", "title": "Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC", "description": "Each participant received one dose of a 5 mg saxagliptin tablet once a day (QD) and a 1000 mg Glucophage\u00ae IR tablet twice a day (BID) on Day 1. On Days 2 through 6, participants received a 1000 mg tablet of Glucophage\u00ae IR BID, and on Day 7, participants received one dose of two 2.5 mg saxagliptin/1000 mg metformin XR FDC tablets. Finally, on Day 8 participants received four 500 mg Glucophage\u00ae IR tablets QD. All study drugs were administered with food."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "2"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEDIAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "13.0", "lowerLimit": "10.0", "upperLimit": "16.0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "2"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Black/African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Adverse Events (AEs) , Serious Adverse Events (SAEs), AEs Leading to Discontinuation, Death", "description": "AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.", "populationDescription": "All participants who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Day 1 up to Day 8, plus 30 days", "groups": [{"id": "OG000", "title": "Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC", "description": "Each participant received one dose of a 5 mg saxagliptin tablet once a day (QD) and a 1000 mg Glucophage\u00ae IR tablet twice a day (BID) on Day 1. On Days 2 through 6, participants received a 1000 mg tablet of Glucophage\u00ae IR BID, and on Day 7, participants received one dose of two 2.5 mg saxagliptin/1000 mg metformin XR FDC tablets. Finally, on Day 8 participants received four 500 mg Glucophage\u00ae IR tablets QD. All study drugs were administered with food."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}]}], "classes": [{"title": "AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Treatment-Related AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "AE Leading to Discontinuation", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Marked Chemistry or Hematology Laboratory Abnormalities", "description": "Lower limit of normal (LLN); upper limit of normal (ULN); treatment (RX); pre-treatment (Pre-Rx); units per liter (U/L); millimoles per liter (mmol/L). Alkaline phosphatase U/L:\\>1.25\\*Pre-RX if Pre-RX \\>ULN or \\>1.25\\*ULN if Pre-RX \\<=ULN; aspartate aminotransferase U/L: \\>1.25\\*Pre-RX if Pre-RX\\>ULN or 1.25\\*ULN if Pre-RX\\<=ULN;alanine aminotransferase U/L: \\>1.25\\*Pre-RX if Pre-RX\\>ULN or 1.25\\*ULN if Pre-RX\\<=ULN;blood urea nitrogen mmol/L: \\>1.1\\*ULN if Pre-RX \\<=ULN or \\>1.2\\*Pre-RX if Pre-RX \\>ULN; total bilirubin \u00b5mol/L: \\>1.1\\*ULN if Pre-RX \\<=ULN or \\>1.25\\*Pre-RX if Pre-RX \\>ULN; creatine phosphokinase U/L: \\>1.5\\*Pre-RX if Pre-RX\\>ULN or \\>1.5\\*ULN if Pre-RX \\<= ULN. Grams per liter (g/L); cells per liter (c/L). Hemoglobin (g/L): \\<0.85\\* pre-RX; hematocrit (%): \\<0.85\\*pre-RX;erythrocytes (\\*10\\^12 c/L): \\<0.85\\*pre-RX; platelet count (\\*10\\^9 c/L): \\<0.85\\*LLN if pre-RX\\>=LLN, or if Pre-Tx \\<LLN; leukocytes (\\*10\\^9 c/L): \\<0.85\\*LLN if pre-RX \\<LLN,or \\<0.9\\*LLN if LLN\\<=Pre-RX\\<=ULN.", "populationDescription": "Participants who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Day 1 to Day 8", "groups": [{"id": "OG000", "title": "Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC", "description": "Each participant received one dose of a 5 mg saxagliptin tablet once a day (QD) and a 1000 mg Glucophage\u00ae IR tablet twice a day (BID) on Day 1. On Days 2 through 6, participants received a 1000 mg tablet of Glucophage\u00ae IR BID, and on Day 7, participants received one dose of two 2.5 mg saxagliptin/1000 mg metformin XR FDC tablets. Finally, on Day 8 participants received four 500 mg Glucophage\u00ae IR tablets QD. All study drugs were administered with food."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Day 1 up to Day 8, plus 30 days.", "description": "Study initiated February 2013 and was terminated November 2013. Last patient, last visit was June 2013.", "eventGroups": [{"id": "EG000", "title": "Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC", "description": "Each participant received one dose of a 5 mg saxagliptin tablet once a day (QD) and a 1000 mg Glucophage\u00ae IR tablet twice a day (BID) on Day 1. On Days 2 through 6, participants received a 1000 mg tablet of Glucophage\u00ae IR BID, and on Day 7, participants received one dose of two 2.5 mg saxagliptin/1000 mg metformin XR FDC tablets. Finally, on Day 8 participants received four 500 mg Glucophage\u00ae IR tablets QD. All study drugs were administered with food.", "seriousNumAffected": 0, "seriousNumAtRisk": 2, "otherNumAffected": 2, "otherNumAtRisk": 2}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 2}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Due to the small number of participants (2), the primary endpoints, pharmacokinetic parameters, were not calculated."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period \u226460 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."}, "pointOfContact": {"title": "Bristol-Myers Squibb Study Director", "organization": "Bristol-Myers Squibb", "email": "Clinical.Trials@bms.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000502994", "term": "Saxagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Manufacturer", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}